



This document is scheduled to be published in the Federal Register on 10/02/2012 and available online at <http://federalregister.gov/a/2012-24194>, and on [FDsys.gov](http://FDsys.gov)

Billing Code 4410-09-M

DEPARTMENT OF JUSTICE  
DRUG ENFORCEMENT ADMINISTRATION  
MANUFACTURER OF CONTROLLED SUBSTANCES  
NOTICE OF REGISTRATION  
APERTUS PHARMACEUTICALS, LLC.

By Notice dated June 4, 2012, and published in the Federal Register on June 12, 2012, 77 FR 35058, Apertus Pharmaceuticals, LLC., 331 Consort Drive, St Louis, Missouri 63011, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Alfentanil (9737)	II
Remifentanil (9739)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards for distribution to their customers.

No comments or objections have been received. DEA has considered the factors in 21 USC 823(a), and determined that the registration of Apertus Pharmaceuticals, LLC., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time.

DEA has investigated Apertus Pharmaceuticals, LLC., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 USC 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Joseph T. Rannazzisi  
Deputy Assistant Administrator  
Office of Diversion Control  
Drug Enforcement Administration

DATED: September 25, 2012

[FR Doc. 2012-24194 Filed 10/01/2012 at 8:45 am; Publication Date: 10/02/2012]